Showing 6871-6880 of 8649 results for "".
- Johnson & Johnson Vision Calls on Individuals Worldwide to Prioritize Your Eyes in 2020https://modernod.com/news/johnson-johnson-vision-calls-on-individuals-worldwide-to-prioritize-your-eyes-in-2020/2477309/Johnson & Johnson Vision announced the launch of “Prioritize Your Eyes,” a worldwide effort to raise awareness about the connection of eye health to overall health. Prioritize Your Eyes encourages everyone to take the single most important step to protect their eyes—getting an eye
- LumiThera to Expand Research into Diabetic Retinopathy for Valeda Light Delivery Systemhttps://modernod.com/news/lumithera-to-expand-research-into-diabetic-retinopathy-for-valeda-light-delivery-system/2477299/LumiThera announced it has initiated further studies with the University of Wisconsin-Milwaukee to establish the use of their Photobiomodulation platform in diabetic retinopathy (DR). “Recent research in our labs in both preclinical and clinical areas hav
- SECO 20/20 Unveils Exclusive Lineup of “Special Sessions”https://modernod.com/news/seco-20-20-unveils-exclusive-lineup-of-special-sessions/2477292/SECO 20/20 has announced the list of 11 speakers who will be featured during the event’s Special Sessions. From March 4-8, 2020, SECO 20/20 will bring together optometric professionals from around the globe to discuss the latest innovations, while discovering cutting-edge lab techniques and infor
- Market Scope: Miami, Philadelphia, and Virginia Beach in Top 10 Markets of Glaucoma Treatment Opportunityhttps://modernod.com/news/market-scope-miami-philadelphia-and-virginia-beach-in-top-10-markets-of-glaucoma-treatment-opportunity/2477291/The metro areas of New York, Los Angeles, Dallas, and Chicago account for 13 percent of the US glaucoma and ocular hypertension population. However, on a per capita share basis, most of the metro areas in Florida stand out for glaucoma disease, driven largely by the state’s high median age. Naple
- Lineage Provides Positive Update on Phase 1/2a Clinical Study of OpRegen for the Treatment of Dry Age-Related Macular Degenerationhttps://modernod.com/news/lineage-provides-positive-update-on-phase-i-iia-clinical-study-of-opregen-for-the-treatment-of-dry-age-related-macular-degeneration/2477278/Lineage Cell Therapeutics a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today provided an update from its ongoing phase 1/2a clinical study of OpRegen, the company’s retinal pigment epithelium (RPE) transplant therapy, for the treatment of dry
- Study Finds Fewer Than Half of US Clinical Trials Complied With New Regulations on Reporting Resultshttps://modernod.com/news/study-finds-fewer-than-half-of-us-clinical-trials-complied-with-new-regulations-on-reporting-results/2477242/According to research published in The Lancet on Friday, compliance with US regulations requiring clinical trials to report results within 1 year of completion remains poor, with about one
- Eyevensys Closes $30M Series B Financinghttps://modernod.com/news/eyevensys-closes-30m-series-b-financing/2477210/Eyevensys announced that it has completed a $30 million Series B financing. The company will use the funds to continue the development of its clinical lead candidate EYS606 for the treatment of chronic noninfectious uveitis (NIU), including the launch of its Electro Study. This phase 2 trial, to
- Oxurion Reports Positive Topline Data From Phase 1 Study of THR-687 for Treatment of DMEhttps://modernod.com/news/oxurion-nv-reports-positive-topline-data-from-phase-1-study-evaluating-thr-687-for-treatment-of-dme/2477208/Oxurion has reported positive topline data from a phase 1 study with THR-687, a novel, potent, pan-RGD integrin antagonist for the treatment of diabetic macular edema (DME). The phase 1, open-label, multicenter, single dose escalation study evaluated the safety of a single intravitreal inj
- Market Scope: Ophthalmic Deals Surge in 2018-2019; Most Transactions Involve New Ventureshttps://modernod.com/news/market-scope-ophthalmic-deals-surge-in-2018-2019-most-transactions-involve-new-ventures/2477195/Ophthalmic deals garnered over $9 billion from January 2018 through October 2019, driven largely by dry eye and retina related fundraising. Over 100 transactions occurred during this period, and over 80 percent of transaction are categorized as new ventures. The Novartis acquisition of Xii
- Occupational Radiation Exposure Tied to Higher Cataract Riskhttps://modernod.com/news/occupational-radiation-exposure-tied-to-higher-cataract-risk/2477191/Higher cumulative occupational exposure to low-dose radiation is associated with excess additive risk (EAR) of developing cataract, according to a new study in a large prospective cohort of U.S. radiation technologists, Reuters reported. <